Brief: Modus Therapeutics Gets Regulatory Approval For Study In Italy
03/11/2025 12:12
Nov 3 (Reuters) - Modus Therapeutics Holding AB MODTX.ST: RECEIVES REGULATORY APPROVAL FOR PART 2 OF THE PHASE IIA STUDY IN CKD-WITH ANEMIA PART 2 OF STUDY TO INITIATE IN Q4 2025 Source text: ID:nMFN4gPWPS Further company coverage: MODTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Modus Therapeutics Holding AB
See all newsBrief: Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
Brief: Modus Gets SEK 0.13 Mln Through Exercise Of Warrants
Brief: Modus Therapeutics Resolves On Directed Share Issue Of 20 Million Shares
Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Brief: Modus Therapeutics Q2 Net Income SEK -4.645 Million